| Assessment Status | Rapid Review complete |
| HTA ID | 23035 |
| Drug | Vutrisiran |
| Brand | Amvuttra® |
| Indication | Indicated for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy |
| Assessment Process | |
| Rapid review commissioned | 06/07/2023 |
| Rapid review completed | 03/08/2023 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that vutrisiran not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement following confidential price negotiations. May 2024
